Methods Data were collected by case-note review for all pregnancies in women with Type 2 DM over a 6-year period (1998–2003) at the National Women's Hospital. Two hundred and fourteen pregnancies were included, metformin was taken in 93 pregnancies and continued until delivery in 32; the remaining 121 pregnancies comprised the control group. The principal outcome measures were preeclampsia, perinatal loss and neonatal morbidity.

Results Baseline characteristics differed between groups: women in the metformin group had greater mean (sd) body mass index [35.5(7.6) vs. 33.5(6.6) kg/m², P < 0.05], more chronic hypertension (19% vs. 7%, P < 0.05) and higher mean (sd) first trimester glycated haemoglobin (HbA_1c) levels [8.3(1.9)% vs. 7.5(1.7)%, P < 0.005]. There was no difference between metformin and control groups, respectively, in the rate of preeclampsia (13% vs. 14%, P = 0.84), perinatal loss (3% vs. 2%, P = 0.65) or neonatal morbidity, including rate of prematurity (23% vs. 22%, P = 0.7), admission to the neonatal unit (40% vs. 48%, P = 0.27), respiratory distress (9% vs. 18%, P = 0.07) and treatment with intravenous dextrose (20% vs. 31%, P = 0.08).

Conclusions Pregnant women with Type 2 DM who were treated with metformin had more risk factors for adverse pregnancy outcomes, but no differences in outcomes were seen compared with women not taking metformin. We need randomized trials to address potential benefits of metformin treatment in this population that may be masked by current practice.

References

1 Feig DS, Palda VA. Type 2 diabetes in pregnancy: a growing concern. Lancet 2002; 359: 1690–1692.
10.1016/S0140-6736(02)08599-9
PubMed Web of Science® Google Scholar
2 Caballero AE, Delgado A, Aguilar-Salinas CA, Herrera AN, Castillo JL, Cabrera T et al. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 2004; 89: 3943–3948.
10.1210/jc.2004-0019
CAS PubMed Web of Science® Google Scholar
3 Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs 2003; 63: 1879–1894.
10.2165/00003495-200363180-00001
CAS PubMed Web of Science® Google Scholar
4 Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137: 25–33.
10.7326/0003-4819-137-1-200207020-00009
CAS PubMed Web of Science® Google Scholar
5 Yamashita H, Shao J, Friedman JE. Physiologic and molecular alterations in carbohydrate metabolism during pregnancy and gestational diabetes mellitus. Clin Obstet Gynecol 2000; 43: 87–98.
10.1097/00003081-200003000-00009
CAS PubMed Web of Science® Google Scholar
6 Elliott BD, Schenker S, Langer O, Johnson R, Prihoda T. Comparative placental transport of oral hypoglycemic agents in humans: a model of human placental drug transfer. Am J Obstet Gynecol 1994; 171: 653–660.
10.1016/0002-9378(94)90078-7
CAS PubMed Web of Science® Google Scholar
7 Elliott BD, Langer O, Schuessling BA. Human placental glucose uptake and transport are not altered by the oral antihyperglycemic agent metformin. Am J Obstet Gynecol 1997; 176: 527–530.
10.1016/S0002-9378(97)70541-6
CAS PubMed Web of Science® Google Scholar
8 Hague W, Davoren P, McIntyre H. Metformin crosses the placenta. Abst. Medicine and Pregnancy. Fremantle, 2003. Australia: Novo Nordisk.
Google Scholar
9 Piacquadio K, Hollingsworth DR, Murphy H. Effects of in-utero exposure to oral hypoglycaemic drugs. Lancet 1991; 338: 866–869.
10.1016/0140-6736(91)91512-S
CAS PubMed Web of Science® Google Scholar
10 Gutzin SJ, Kozer E, Magee LA, Feig DS, Koren G. The safety of oral hypoglycemic agents in the first trimester of pregnancy: a meta-analysis. Can J Clin Pharmacol 2003; 10: 179–183.
PubMed Google Scholar
11 Coetzee EJ, Jackson WP. Oral hypoglycaemics in the first trimester and fetal outcome. S Afr Med J 1984; 65: 635–637.
CAS PubMed Web of Science® Google Scholar
12 Harborne L, Fleming R, Lyall H, Sattar N. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet 2003; 361: 1894–1901.
10.1016/S0140-6736(03)13493-9
CAS PubMed Web of Science® Google Scholar
13 Glueck CJ, Goldenberg N, Pranikoff J, Loftspring M, Sieve L, Wang P. Height, weight, and motor-social developments during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum Reprod 2004; 19: 1323–1330.
10.1093/humrep/deh263
CAS PubMed Web of Science® Google Scholar
14 Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002; 17: 2858–2864.
10.1093/humrep/17.11.2858
CAS PubMed Web of Science® Google Scholar
15 Glueck CJ, Bornovali S, Pranikoff J, Goldenberg N, Dharashivkar S, Wang P. Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome. Diabet Med 2004; 21: 829–836.
10.1111/j.1464-5491.2004.01251.x
CAS PubMed Web of Science® Google Scholar
16 Hellmuth E, Damm P, Molsted-Pederson L. Congenital malformations in offspring of diabetic women treated with oral hypoglycaemic agents during embryogenesis. Diabet Med 1994; 11: 471–474.
10.1111/j.1464-5491.1994.tb00308.x
CAS PubMed Web of Science® Google Scholar
17 Glueck CJ, Phillips H, Cameron D, Sieve-Smith L, Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 2001; 75: 46–52.
10.1016/S0015-0282(00)01666-6
CAS PubMed Web of Science® Google Scholar
18 Jakubowicz DJ, Iuorno MJ, Jacubowicz S, Roberts KA, Nestler JE. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87: 524–529.
10.1210/jcem.87.2.8207
CAS PubMed Web of Science® Google Scholar
19 Heard MJ, Pierce A, Carson SA, Buster JE. Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome. Fertil Steril 2002; 77: 669–673.
10.1016/S0015-0282(01)03266-6
PubMed Web of Science® Google Scholar
20 Glueck CJ, Goldenberg N, Wang P, Loftspring M, Sherman A. Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy. Hum Reprod 2004; 19: 510–524.
10.1093/humrep/deh109
CAS PubMed Web of Science® Google Scholar
21 Glueck CJ, Wang P, Kobayashi S, Phillips H, Sieve-Smith L. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 2002; 77: 520–525.
10.1016/S0015-0282(01)03202-2
CAS PubMed Web of Science® Google Scholar
22 Coetzee EJ, Jackson WP. Pregnancy in established non-insulin-dependent diabetics. S Afr Med J 1980; 58: 795–802.
CAS PubMed Web of Science® Google Scholar
23 Coetzee EJ, Jackson WP. Metformin in management of pregnant insulin-independent diabetics. Diabetologia 1979; 16: 241–245.
10.1007/BF01221950
CAS PubMed Web of Science® Google Scholar
24 Coetzee EJ, Jackson WP. The management of non-insulin-dependent diabetes during pregnancy. Diabetes Res 1986; 1: 281–287.
10.1016/S0168-8227(86)80036-5
CAS Google Scholar
25 Vanky E, Salvesen KA, Heimstad R, Fougner KJ, Romunstad P, Carlsen SM. Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomised study. Hum Reprod 2004; 19: 1734–1740.
10.1093/humrep/deh347
CAS PubMed Web of Science® Google Scholar
26 Hellmuth E, Damm P, Molsted-Pederson L. Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabet Med 2000; 17: 507–511.
10.1046/j.1464-5491.2000.00314.x
CAS PubMed Web of Science® Google Scholar
27 Thadhani R, Stampfer MJ, Hunter DJ, Manson JE, Solomon CG, Curhan GC. High body mass index and hypercholesterolemia: risk of hypertensive disorders of pregnancy. Obstet Gynecol 1999; 94: 543–550.
10.1097/00006250-199910000-00011
CAS PubMed Web of Science® Google Scholar
28 Weiss JL, Malone FD, Emig D, Ball RH, Nyberg DA, Comstock CH et al. Obesity, obstetric complications and cesarean delivery rate—a population-based screening study. Am J Obstet Gynecol 2004; 190: 1091–1097.
10.1016/j.ajog.2003.09.058
PubMed Web of Science® Google Scholar
29 O'Brien TE, Ray JG, Chan WS. Maternal body mass index and the risk of preeclampsia: a systematic overview [see comment]. Epidemiology 2003; 14: 368–374.
10.1097/01.EDE.0000059921.71494.D1
PubMed Web of Science® Google Scholar
30 Brown MA, Hague WM, Higgins J, McCowan L, Oats J, Peek MJ, Rowan JA, Walters BN. The detection, investigation and management of hypertension in pregnancy: full consensus statement. Aust N Z J Obstet Gynaecol 2000; 40: 139–155.
10.1111/j.1479-828X.2000.tb01137.x
CAS PubMed Web of Science® Google Scholar
31 Beeby PJ, Bhutap T, Taylor LK. New South Wales population-based birthweight percentile charts. J Paediatr Child Health 1996; 32: 512–518.
10.1111/j.1440-1754.1996.tb00965.x
CAS PubMed Web of Science® Google Scholar
32 Cundy T, Slee F, Gamble G, Neale L. Hypertensive disorders of pregnancy in type 1 and type 2 diabetes. Diabet Med 2002; 19: 482–489.
10.1046/j.1464-5491.2002.00729.x
CAS PubMed Web of Science® Google Scholar
33 Dunne F, Brydon P, Smith K, Gee H. Pregnancy in women with type 2 diabetes: 12 years outcome data 1990–2002. Diabet Med 2003; 20: 734–738.
10.1046/j.1464-5491.2003.01017.x
CAS PubMed Web of Science® Google Scholar
34 Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a link to diabetes and heart disease. Obes Res 2003; 11: 1278–1289.
10.1038/oby.2003.174
CAS PubMed Web of Science® Google Scholar
35 de Vries MJ, Dekker GA, Schoemaker J. Higher risk of preeclampsia in the polycystic ovary syndrome: a case control study. Eur J Obstet Gynecol Reprod Biol 1998; 76: 91–95.
10.1016/S0301-2115(97)00164-4
PubMed Web of Science® Google Scholar
36 Wolf M, Sandler L, Munoz K, Hsu K, Ecker JL, Thadhani R. First trimester insulin resistance and subsequent preeclampsia: a prospective study. J Clin Endocrinol Metab 2002; 87: 1563–1568.
10.1210/jcem.87.4.8405
CAS PubMed Web of Science® Google Scholar
37 Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999; 180: 499–506.
10.1016/S0002-9378(99)70239-5
CAS PubMed Web of Science® Google Scholar
38 Dabelea D, Hanson RL, Lindsay RS, Pettitt DJ, Imperatore G, Gabir MM et al. Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity. Diabetes 2000; 49: 2208–2211.
Google Scholar
39 Silverman BL, Metzger BE, Cho NH, Loeb CA. Impaired glucose tolerance in adolescent offspring of diabetic mothers. Diabetes Care 1995; 18: 611–617.
10.2337/diacare.18.5.611
CAS PubMed Web of Science® Google Scholar
40 Metzger BE, Silverman BL, Freinkel N, Dooley SL, Ogata ES, Green OC. Amniotic fluid insulin concentration as a predictor of obesity. Arch Dis Child 1990; 65: 1050–1052.
10.1136/adc.65.10_Spec_No.1050
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume23, Issue3

March 2006

Pages 318-322

Pregnancy in women with Type 2 diabetes: who takes metformin and what is the outcome?

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Pregnancy in women with Type 2 diabetes: who takes metformin and what is the outcome?

Abstract

References

Citing Literature

References

Related

Information